Evaluation Optimizing Myeloma Therapies For Older And More Frail Patients Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). Did this activity meet your educational needs? Yes No Did this activity increase your competence? Yes No Do you feel like there were any new data presented during this activity? Yes - please explain: No Did you learn anything new? Yes, please specify: No Did you gain confidence in your ability to act on the new information? Yes - please explain: No Did this activity include opportunities to learn as a part of a healthcare team? Yes - please explain: No Please answer the following question using a 5-point likert scale (5 = a great deal, 3 = a modest amount, 1 = nothing at all). How much did you learn as a result of this session? 5 4 3 2 1 Please rate the following components related to this activity using a 5-point likert scale (5 = excellent, 3 = good, 1 = poor). Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Overall 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Joshua Richter, MD 5 4 3 2 1 Joseph Mikhael, MD, MEd, FRCPC, FACP 5 4 3 2 1 To what extent were the following learning objectives addressed by this activity (5 = entirely, 3 = moderately, 1 = not at all)? Explain the significance of the underrepresentation of older adults (65+) and/or the frail population in multiple myeloma clinical trials 5 4 3 2 1 Utilize clinical data and real-world evidence to develop individual treatment plans for older adult patients, considering frailty and factors such as comorbidities and susceptibility to adverse events 5 4 3 2 1 Identify relapsed/refractory MM management strategies, incorporating novel therapeutic targets to overcome the challenges of tolerability, adverse events, and managing comorbidities 5 4 3 2 1 The information presented in this activity was free of commercial bias. Agree Disagree How many patients do you encounter with MM on a monthly basis? 10 or fewer 20 30 40 50 or more Please now rate your ability to use currently available therapies to manage MM. Excellent Very Good Good Fair Poor Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No Which of the following barriers do you perceive in your efforts to implement practice changes and/or optimize patient care? Select all that apply. No barriers Cost Lack of opportunity/patients Lack of administrative support Insurance/reimbursement issues Lack of consensus or professional guidelines Lack of time to assess/counsel patients Patient compliance issues Not applicable to my practice Other: How might future activities help you address those barriers? 255 characters max Despite the median age of diagnosis of 70 years old, the median age of multiple myeloma patients participating in clinical trials is _________. 52 years old 62 years old 72 years old 82 years old Based on the Tourmaline US-MM6 study, in-class transition from bortezomib to which of the following treatments improved responses in community-treated multiple myeloma patients aged 65 or older? Carfilzomib Daratumumab Ixazomib Elotozumab Which of the following adverse events may be avoided by using second-generation proteasome inhibitors? Anemia Diarrhea Fatigue Neuropathy How confident are you in your ability to tailor treatment plans for multiple myeloma patients over the age of 65? Very confident Confident Somewhat confident Not very confident Not at all confident Based on my participation in this activity, I anticipate I will more often: (select all that apply) Discern clinical trial limitations when applying the latest clinical evidence particularly for more frail MM patients Develop MM treatment strategies for older and/or more frail individuals considering comorbidities and susceptibility to adverse events. Make informed recommendations based on real-world evidence when treating MM patients with comorbidities. Utilize MM therapies which are associated with lower risk of adverse event for older patients. Integrate approaches to help overcome common barriers to care, including treatment adherence and tolerability. Other (please specify): Previous